EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Outcomes With Limus- vs Paclitaxel-Coated Balloons for Percutaneous Coronary Intervention

Ramy Sedhom, Mohamed Hamed, Ayman Elbadawi, Amr Mohsen, Pooja Swamy, Ahmed Athar, Aditya S Bharadwaj, Vinoy Prasad, Islam Y Elgendy, Fernando Alfonso

JACC: Cardiovascular Interventions · 2024-07 · 17 (13) · 1533-1543

DOI: 10.1016/j.jcin.2024.04.042 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift JACC: Cardiovascular Interventions, 2024-07. Verfasst von Ramy Sedhom und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Loma Linda University Medical Center, Loma Linda, California, USA. Hauptthemen laut MEDLINE: Angioplasty, Balloon, Coronary, Cardiac Catheters, Cardiovascular Agents, Coated Materials, Biocompatible. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Randomized controlled trials (RCTs) examining the outcomes with limus drug-coated balloons (DCBs) vs paclitaxel DCBs were small and underpowered for clinical endpoints. OBJECTIVES: This study sought to compare the angiographic and clinical outcomes with limus DCBs vs paclitaxel DCBs for percutaneous coronary intervention (PCI). METHODS: An electronic search of Medline, EMBASE, and Cochrane databases was performed through January 2024 for RCTs comparing limus DCBs vs paclitaxel DCBs for PCI. The primary endpoint was clinically driven target lesion revascularization (TLR). The secondary endpoints were late angiographic findings. Summary estimates were constructed using a random effects model. RESULTS: Six RCTs with 821 patients were included; 446 patients received a limus DCB, and 375 patients received a paclitaxel DCB. There was no difference between limus DCBs and paclitaxel DCBs in the incidence of TLR at a mean of 13.4 months (10.3% vs 7.8%; risk ratio [RR]: 1.32; 95% CI: 0.84-2.08). Subgroup analysis suggested no significant interaction among studies for de novo coronary lesions vs in-stent restenosis (Pinteraction = 0.58). There were no differences in the risk of major adverse cardiovascular events, cardiac mortality, or target vessel myocardial infarction between groups. However, limus DCBs were associated with a higher risk of binary restenosis (RR: 1.89; 95% CI: 1.14-3.12), late lumen loss (mean difference = 0.16; 95% CI: 0.03-0.28), and a smaller minimum lumen diameter (mean difference = -0.12; 95% CI: -0.22 to -0.02) at late follow-up. In addition, late lumen enlargement occurred more frequently (50% vs 27.5%; RR: 0.59; 95% CI: 0.45-0.77) with paclitaxel DCBs. CONCLUSIONS: Among patients undergoing DCB-only PCI, there were no differences in the risk of clinically driven TLR and other clinical outcomes between limus DCBs and paclitaxel DCBs. However, paclitaxel DCBs were associated with better late angiographic outcomes. These findings support the need for future trials to establish the role of new-generation limus DCBs for PCI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioplasty, Balloon, CoronaryCardiac CathetersCardiovascular AgentsCoated Materials, BiocompatibleCoronary Artery DiseasePaclitaxelPercutaneous Coronary InterventionAgedFemaleHumansMaleMiddle AgedCoronary AngiographyCoronary RestenosisRandomized Controlled Trials as TopicRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

biolimusdrug-coated balloonpaclitaxelsirolimus

Substanzen

Cardiovascular AgentsCoated Materials, BiocompatiblePaclitaxel

Autor:innen und Institutionen

  • Division of Cardiology, Loma Linda University Medical Center, Loma Linda, California, USA.
  • Division of Cardiology, Florida Atlantic University, Boca Raton, Florida, USA.
  • Division of Cardiology, Christus Good Shepherd Medical Center, Longview, Texas, USA; Texas A&M School of Medicine, Bryan, Texas, USA.
  • Cardiology Section, Jerry L. Pettis Memorial Veteran's Hospital, Loma Linda, California, USA.
  • Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, Kentucky, USA. Electronic address: iyelgendy@gmail.com.
  • Cardiology Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, IIS-IP, CIBER-CV, Madrid, Spain.

Zitieren

APA

Sedhom, R., Hamed, M., Elbadawi, A., Mohsen, A., Swamy, P., Athar, A., Bharadwaj, A. S., Prasad, V., Elgendy, I. Y., & Alfonso, F. (2024). Outcomes With Limus- vs Paclitaxel-Coated Balloons for Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 17(13), 1533-1543. https://doi.org/10.1016/j.jcin.2024.04.042

Vancouver

Sedhom R, Hamed M, Elbadawi A, Mohsen A, Swamy P, Athar A, et al. Outcomes With Limus- vs Paclitaxel-Coated Balloons for Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. 2024;17(13):1533-1543. doi:10.1016/j.jcin.2024.04.042

BibTeX
@article{Sedhom2024,
  author = {Sedhom, Ramy and Hamed, Mohamed and Elbadawi, Ayman and Mohsen, Amr and Swamy, Pooja and Athar, Ahmed and Bharadwaj, Aditya S and Prasad, Vinoy and Elgendy, Islam Y and Alfonso, Fernando},
  title = {Outcomes With Limus- vs Paclitaxel-Coated Balloons for Percutaneous Coronary Intervention},
  journal = {JACC: Cardiovascular Interventions},
  year = {2024},
  volume = {17},
  number = {13},
  pages = {1533--1543},
  doi = {10.1016/j.jcin.2024.04.042}
}
Kostenlos starten →